Drug Trial Radar · NCT05832229
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
260
Planned (sponsor's estimate)
Start
Dec 7, 2023
Primary completion
Aug 31, 2029
Study completion Aug 31, 2029
Sponsor
- Sponsor type
- NIH
- Collaborators
- The Cleveland Clinic; Columbia University; Weill Medical College of Cornell University; Duke University; Mayo Clinic; University of Miami; University of Michigan; University of California, San Diego; University of California, San Francisco; LAC+USC Medical Center; Virginia Commonwealth University; National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Cancer Institute (NCI); University of Southern California
- First posted
- Apr 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.
Conditions
- Cirrhosis
- Cirrhosis, Liver
- Cirrhosis Early
- Cirrhosis Due to Hepatitis B
- Cirrhosis Advanced
- Cirrhosis Infectious
- Cirrhosis Alcoholic
- Cirrhosis Due to Hepatitis C
Interventions
RosuvastatinDrug
Patients meeting all eligibility criteria will be assigned to a randomization arm prior to initiation of a 4-week lead-in phase of the study. All participants will undergo a 4-week, open-label active run-in phase to evaluate initial safety and adherence to rosuvastatin. During this active run-phase, all participants will receive target dose rosuvastatin-- 20 mg daily . After the active run-in phase, all participants will continue with their pre-assigned randomization (1:1) treatment of rosuvastatin 20 mg daily or matching placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change in liver stiffnessTime frame: 96 weeks
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
University of California San Diego NAFLD Research Center
La Jolla, California · Recruiting
Keck Medical Center of USC
Los Angeles, California · Recruiting
LAC + USC Medical Center
Los Angeles, California · Recruiting
UCSF/Zuckerberg San Francisco General Hospital and Trauma Center
San Francisco, California · Recruiting
UCSF Medical Center
San Francisco, California · Recruiting
University of Miami Health System
Miami, Florida · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
New York Presbyterian/Weill Cornell
New York, New York · Recruiting
Columbia University Iriving School of Medicine
New York, New York · Recruiting
Duke Liver Center
Durham, North Carolina · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
Virginia Commonwealth University
Richmond, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.